Mortality risk for patients with hidradenitis suppurativa (HS) is largely unknown.
To compare mortality risk among patients with and without HS in the United States.
Retrospective cohort study in a population sample identified using electronic health records data between January 1, 2012 and December 31, 2016. Primary outcome was incidence of 5-year all-cause mortality.
Crude 5-year mortality rate among HS patients was 2.4% (321/13,289), compared to 2.7% (18,508/685,573) among controls. In the fully adjusted model, increase in HS mortality risk was 14% [OR 1.14, 95% CI 1.01-1.28]. Overall, excess risk of death attributable to HS was 3.1 deaths per 1,000 patients (95% CI 0.2 – 6.0) during the study period. Characteristics associated with mortality among HS patients included age (OR 1.05, 95% CI 1.04-1.06), male sex (OR 1.40, 95% CI 1.09-1.79), ever smoking status (OR 1.48, 95% CI 1.16-1.92), and CCI score (OR 1.25, 95% CI 1.21-1.29).
Follow-up period may not have been long enough to assess influence of disease severity or duration on mortality.
HS appears to confer an independent risk of all-cause mortality. This risk is also influenced by tobacco smoking and comorbidities, which may be modifiable.